This milestone has paved the way for other FDA-approved GLP-1 analogs, such as liraglutide and semaglutide, with half-lives of 11 to 13 h and 144 to 168 h, respectively [106,107] (Table 1), highlighting the broad therapeutic potential of GLP-1RAs in treating systemic diseases, including type 2 diabetes and obesity. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.